The Microbiome Sequencing Services Market size is estimated at USD 1.71 billion in 2024, and is expected to reach USD 2.36 billion by 2029, growing at a CAGR of 6.70% during the forecast period (2024-2029).
During the COVID-19 pandemic, several studies were focused on the impact of the SARS-CoV-2 virus on the health of the human population. The microbiome sequencing services have extensively helped in studying the COVID-19 impact on the human microbiome. For instance, an article published in the Journal of Frontiers in Medicine in March 2021 explored the direct and indirect influences of the pandemic on the gut microbiome and how these can affect research and clinical trials.
The study showed an extensive interaction between the gut microbiome and the SARS-CoV-2 virus. The disrupted gut microbiome contributed to the course and severity of COVID-19, as the loss of beneficial microbes, the proliferation of potentially harmful microbes, and the reduction of microbial diversity contributed to the worsening of health. Thus, the increased use of microbiome sequencing services during the COVID-19 pandemic significantly impacted the growth of the market. However, as the pandemic has subsided currently, the usage of microbiome sequencing is stable due to increased focus on research of other diseases. Thus, the studied market is expected to have normal growth during the forecast period of the study.
Major factors that are driving the market growth include huge investment in microbiome research, a rise in demand for NGS services, the surge in genomic research, and the widening application area of microbiome sequencing.
The increasing demand for Next-Generation Sequencing is a major factor attributing to the growth of the microbiome sequencing services market. For instance, an article published in the Journal of Clinical Investigation in April 2022 indicated that Next-generation sequencing (NGS) technology has advanced the understanding of the human microbiome by allowing for the discovery and characterization of unculturable microbes with the prediction of their function. Such innovations in the next-generation sequencing services are expected to boost the growth of the microbiome sequencing services market.
The rise in genomic research all over the world is also contributing to the growth of the microbiome sequencing services market in the forecast period. For instance, according to the National Human Genome Research Institute of the United States National Institute of Health, data on Genomic Data Science updated in April 2022, indicated that as biomedical research projects and large-scale collaborations grow rapidly, the amount of genomic data being generated is also increasing, with roughly 2 to 40 billion gigabytes of data being generated every year. A large number of research and development projects in genomic research are adding to the growth of the microbiome sequencing services market.
Additionally, in June 2021, Illumina and Microba Life Sciences launched a partnership to improve the understanding of the human gut microbiome in human health and diseases. The partnership will combine Illumina's revolutionary NGS tools and Microba's high-quality proprietary gut microbiome analysis platform to produce the accurate metagenomic data required by researchers to fuel discoveries. Such research collaborations are also adding to the growth of the studied market.
Thus, the aforementioned factors, such as the increasing genomic research, innovations in NGS technology, and the rising developments by market players, are expected to boost the market growth. However, ethical and legal issues related to genome sequencing and the lack of skilled technicians for NGS data analysis are hindering the growth of the microbiome sequencing services market in the forecast period.
The rising number of cancer cases around the world is also adding to the developments in the microbiome sequencing services market. For instance, according to the data updated by Cancer Australia in 2022, it was estimated that 162,163 new cases of cancer would be diagnosed in Australia in 2022, out of which 88,982 would be males and 73,181 females. The source also stated that it was estimated that around 2 in 5 people (or 43%) would be diagnosed with cancer by age 85 in Australia. The large increase in the number of cases over the years is majorly contributing to the increase in cancer genomic research for efficient treatment studies, which in turn will propel the growth of the microbiome sequencing services market in the forecast period.
Moreover, the developments by key players in the market are also expected to enhance the market growth. For instance, in June 2022, Cordlife Group and AMILI signed a strategic partnership to provide a gut microbiome banking service in Singapore and the surrounding region. The gut microbiome data would help in future fecal microbiota transplants (FMT) for diseases such as colorectal cancer.
The research and development by key market players in the segment are also adding to the market growth. For instance, in March 2022, Microbiotica raised USD 67 million for its research on microbiome-based immuno-oncology through phase 1b trials, which are to be started later in the year. Such contributions by the market players are expected to propel market growth.
Thus, the aforementioned factors, such as the rising prevalence of cancer, increasing research spending on cancer genomics, and the rising research and development by key market players, are expected to boost the market growth.
The rising number of cancer cases in the North American region is adding to the growth of the microbiome sequencing services market. For instance, as per the Canada Cancer Society's statistics for 2022, around 233,900 Canadians were expected to be diagnosed with cancer in 2022, out of which 121,100 were men and 112,800 were women. Also, as per the American Cancer Society's data for 2023, around 1.95 million new cases of cancer are expected to be diagnosed in the United States in 2023. Thus, the large population affected by cancer and the increase in the necessity of microbiome sequencing services for the ease of diagnosis and treatment of such diseases is expected to propel the growth of the microbiome sequencing services market in the forecast period.
Moreover, researchers from Rutgers University, United States, in their article published in the Journal of Genome Medicine in February 2021, discussed the use of a guild to identify potentially important functional microbiomes associated with specific health outcomes and disease phenotypes through next-generation sequencing. The article suggested that guild-based analysis may create a paradigm shift towards an ecologically meaningful approach to understanding the relationship between the gut microbiome and human health. The rise in the research studies on the microbiome through the use of sequencing services in the United States is likely to add to the growth of the studied market over the forecast period.
Moreover, the developments by key players in the market are also expected to enhance the market growth. For instance, in May 2021, Viome scored an FDA breakthrough labeling for its cancer-screening, microbiome-sequencing AI platform.
Thus, the increasing necessity for microbiome sequencing services coupled with increasing investment in the health care department is known to propel the growth of the market in this region.
This product will be delivered within 2 business days.
During the COVID-19 pandemic, several studies were focused on the impact of the SARS-CoV-2 virus on the health of the human population. The microbiome sequencing services have extensively helped in studying the COVID-19 impact on the human microbiome. For instance, an article published in the Journal of Frontiers in Medicine in March 2021 explored the direct and indirect influences of the pandemic on the gut microbiome and how these can affect research and clinical trials.
The study showed an extensive interaction between the gut microbiome and the SARS-CoV-2 virus. The disrupted gut microbiome contributed to the course and severity of COVID-19, as the loss of beneficial microbes, the proliferation of potentially harmful microbes, and the reduction of microbial diversity contributed to the worsening of health. Thus, the increased use of microbiome sequencing services during the COVID-19 pandemic significantly impacted the growth of the market. However, as the pandemic has subsided currently, the usage of microbiome sequencing is stable due to increased focus on research of other diseases. Thus, the studied market is expected to have normal growth during the forecast period of the study.
Major factors that are driving the market growth include huge investment in microbiome research, a rise in demand for NGS services, the surge in genomic research, and the widening application area of microbiome sequencing.
The increasing demand for Next-Generation Sequencing is a major factor attributing to the growth of the microbiome sequencing services market. For instance, an article published in the Journal of Clinical Investigation in April 2022 indicated that Next-generation sequencing (NGS) technology has advanced the understanding of the human microbiome by allowing for the discovery and characterization of unculturable microbes with the prediction of their function. Such innovations in the next-generation sequencing services are expected to boost the growth of the microbiome sequencing services market.
The rise in genomic research all over the world is also contributing to the growth of the microbiome sequencing services market in the forecast period. For instance, according to the National Human Genome Research Institute of the United States National Institute of Health, data on Genomic Data Science updated in April 2022, indicated that as biomedical research projects and large-scale collaborations grow rapidly, the amount of genomic data being generated is also increasing, with roughly 2 to 40 billion gigabytes of data being generated every year. A large number of research and development projects in genomic research are adding to the growth of the microbiome sequencing services market.
Additionally, in June 2021, Illumina and Microba Life Sciences launched a partnership to improve the understanding of the human gut microbiome in human health and diseases. The partnership will combine Illumina's revolutionary NGS tools and Microba's high-quality proprietary gut microbiome analysis platform to produce the accurate metagenomic data required by researchers to fuel discoveries. Such research collaborations are also adding to the growth of the studied market.
Thus, the aforementioned factors, such as the increasing genomic research, innovations in NGS technology, and the rising developments by market players, are expected to boost the market growth. However, ethical and legal issues related to genome sequencing and the lack of skilled technicians for NGS data analysis are hindering the growth of the microbiome sequencing services market in the forecast period.
Microbiome Sequencing Services Market Trends
The Oncology Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Oncology holds a significant market share due to the rising number of cancer cases all over the world, and the increasing cancer genomic research is expected to boost the growth of the microbiome sequencing services market. For instance, according to the data published by the National Institute of Health (NIH) in March 2023, the research spending on cancer genomics in the United States is expected to increase from USD 1,232 million in 2022 to USD 1,300 million in 2023. Thus, the increasing research spending on the microbiome of cancer is boosting the growth of the oncology segment in the microbiome sequencing services market in the forecast period.The rising number of cancer cases around the world is also adding to the developments in the microbiome sequencing services market. For instance, according to the data updated by Cancer Australia in 2022, it was estimated that 162,163 new cases of cancer would be diagnosed in Australia in 2022, out of which 88,982 would be males and 73,181 females. The source also stated that it was estimated that around 2 in 5 people (or 43%) would be diagnosed with cancer by age 85 in Australia. The large increase in the number of cases over the years is majorly contributing to the increase in cancer genomic research for efficient treatment studies, which in turn will propel the growth of the microbiome sequencing services market in the forecast period.
Moreover, the developments by key players in the market are also expected to enhance the market growth. For instance, in June 2022, Cordlife Group and AMILI signed a strategic partnership to provide a gut microbiome banking service in Singapore and the surrounding region. The gut microbiome data would help in future fecal microbiota transplants (FMT) for diseases such as colorectal cancer.
The research and development by key market players in the segment are also adding to the market growth. For instance, in March 2022, Microbiotica raised USD 67 million for its research on microbiome-based immuno-oncology through phase 1b trials, which are to be started later in the year. Such contributions by the market players are expected to propel market growth.
Thus, the aforementioned factors, such as the rising prevalence of cancer, increasing research spending on cancer genomics, and the rising research and development by key market players, are expected to boost the market growth.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period
The rise in the adoption of highly advanced techniques and systems in microbiome sequencing services and the technological advancements made in genomic research studies are expected to boost the growth of the market in the North American region. The high awareness among healthcare personnel of the availability of innovative microbiome sequencing services in the market contributes to the high market growth in the region.The rising number of cancer cases in the North American region is adding to the growth of the microbiome sequencing services market. For instance, as per the Canada Cancer Society's statistics for 2022, around 233,900 Canadians were expected to be diagnosed with cancer in 2022, out of which 121,100 were men and 112,800 were women. Also, as per the American Cancer Society's data for 2023, around 1.95 million new cases of cancer are expected to be diagnosed in the United States in 2023. Thus, the large population affected by cancer and the increase in the necessity of microbiome sequencing services for the ease of diagnosis and treatment of such diseases is expected to propel the growth of the microbiome sequencing services market in the forecast period.
Moreover, researchers from Rutgers University, United States, in their article published in the Journal of Genome Medicine in February 2021, discussed the use of a guild to identify potentially important functional microbiomes associated with specific health outcomes and disease phenotypes through next-generation sequencing. The article suggested that guild-based analysis may create a paradigm shift towards an ecologically meaningful approach to understanding the relationship between the gut microbiome and human health. The rise in the research studies on the microbiome through the use of sequencing services in the United States is likely to add to the growth of the studied market over the forecast period.
Moreover, the developments by key players in the market are also expected to enhance the market growth. For instance, in May 2021, Viome scored an FDA breakthrough labeling for its cancer-screening, microbiome-sequencing AI platform.
Thus, the increasing necessity for microbiome sequencing services coupled with increasing investment in the health care department is known to propel the growth of the market in this region.
Microbiome Sequencing Services Industry Overview
The microbiome sequencing services market is moderately competitive and consists of a number of major players. The initiatives taken by the market players such as the launch of new services and broader offering is also boosting the growth of the market. Companies like Baseclear BV, Clinical Microbiomics AS, Merieux Nutrisciences Corporations, Microbiome Insights Inc., MR DNA, and Zymo Research Corp., among others, hold substantial shares in the microbiome sequencing services market.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD Millions)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Baseclear BV
- Clinical Microbiomics AS
- Merieux Nutrisciences Corporations (Biofortis)
- Locus Biosciences (EPIBIOME)
- Microbiome Insights Inc.
- MR DNA
- Zymo Research
- Rancho Biosciences
- Metabiomics
- CosmosID
- ZIFO
- Shanghai Realbio Technology (RBT) Co., Ltd.
Methodology
LOADING...
